At the time of the first seizure, 26.8% (15/56) of the patients received disease-modifying-treatment (DMT) for MS, consisting of interferon-beta (14.3%, 8/56), glatiramer acetat (3.6%, 2/56), dimethylfumarat (1.8%, 1/56), fingolimod (1.8%, 1/56), mitoxantron (1.8%, 1/56), natalizumab (1.8%, 1/56), methotrexat (1.8%, 1/56). This evidence concerns the gene IFNB1 and myeloid sarcoma.